Literature DB >> 23831255

Role of angiotensin II type 1 receptor-activating antibodies in solid organ transplantation.

Nancy L Reinsmoen1.   

Abstract

Angiotensin type I receptor (AT1R) mediates physiologic and pathophysiologic actions of its ligand, angiotensin II. Overactivity of the AT1R and angiotensin II interaction results in hypertension and vascular remodeling. Antibodies to AT1R have been implicated in several vascular pathologies. In renal transplantation, elevated levels of anti-AT1R antibodies have been associated with antibody mediated rejection (AMR) in the absence of donor HLA specific antibodies. In heart transplantation, increased levels of anti-AT1R antibodies have been associated with cellular and AMR as well as an early onset of microvasculopathy. This review summarizes the current investigations regarding the impact of anti-AT1R antibodies in solid organ transplantation and provides insight into the humoral response in the presence of non-HLA and HLA specific antibodies.
Copyright © 2013 American Society for Histocompatibility and Immunogenetics. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23831255     DOI: 10.1016/j.humimm.2013.06.034

Source DB:  PubMed          Journal:  Hum Immunol        ISSN: 0198-8859            Impact factor:   2.850


  9 in total

Review 1.  Set Up for Failure: Pre-Existing Autoantibodies in Lung Transplant.

Authors:  Alexander McQuiston; Amir Emtiazjoo; Peggi Angel; Tiago Machuca; Jason Christie; Carl Atkinson
Journal:  Front Immunol       Date:  2021-08-11       Impact factor: 7.561

Review 2.  Coronary microvasculopathy in heart transplantation: Consequences and therapeutic implications.

Authors:  Alessandra Vecchiati; Sara Tellatin; Annalisa Angelini; Sabino Iliceto; Francesco Tona
Journal:  World J Transplant       Date:  2014-06-24

3.  Investigation of Serum Angiotensin II Type 1 Receptor Antibodies at the Time of Renal Allograft Rejection.

Authors:  Hyeyoung Lee; Ji-Il Kim; In-Sung Moon; Byung Ha Chung; Chul-Woo Yang; Yonggoo Kim; Kyungja Han; Eun-Jee Oh
Journal:  Ann Lab Med       Date:  2015-04-01       Impact factor: 3.464

Review 4.  Endothelial Cells in Antibody-Mediated Rejection of Kidney Transplantation: Pathogenesis Mechanisms and Therapeutic Implications.

Authors:  Shuo Wang; Chao Zhang; Jina Wang; Cheng Yang; Ming Xu; Ruiming Rong; Tongyu Zhu; Dong Zhu
Journal:  J Immunol Res       Date:  2017-02-01       Impact factor: 4.818

5.  Bortezomib-Containing Multimodality Treatment for Antibody-Mediated Rejection with Anti-HLA and Anti-AT1R Antibodies after Kidney Transplantation.

Authors:  Samuele Iesari; Quirino Lai; Evaldo Favi; Francesco Pisani
Journal:  Yonsei Med J       Date:  2017-05       Impact factor: 2.759

6.  Kidney re-transplantation in a child across the barrier of persisting angiotensin II type I receptor antibodies.

Authors:  Annika Gold; Alexander Fichtner; Daniela Choukair; Claus Peter Schmitt; Caner Süsal; Duska Dragun; Burkhard Tönshoff
Journal:  Pediatr Nephrol       Date:  2020-12-23       Impact factor: 3.714

7.  Non-HLA Antibodies in Hand Transplant Recipients Are Connected to Multiple Acute Rejection Episodes and Endothelial Activation.

Authors:  Dorota Sikorska; Dorota Kamińska; Rusan Catar; Mirosław Banasik; Harald Heidecke; Kai Schulze-Forster; Katarzyna Korybalska; Rafał Rutkowski; Joanna Łuczak; Jerzy Jabłecki; Andrzej Oko; Przemysław Daroszewski; Mariusz Kusztal; Włodzimierz Samborski
Journal:  J Clin Med       Date:  2022-02-04       Impact factor: 4.241

Review 8.  Graft microvascular disease in solid organ transplantation.

Authors:  Xinguo Jiang; Yon K Sung; Wen Tian; Jin Qian; Gregg L Semenza; Mark R Nicolls
Journal:  J Mol Med (Berl)       Date:  2014-06-01       Impact factor: 4.599

Review 9.  What solid organ transplant healthcare providers should know about renin-angiotensin-aldosterone system inhibitors and COVID-19.

Authors:  Sunnie Y Wong; Aleah L Brubaker; Aileen X Wang; Adetokunbo A Taiwo; Marc L Melcher
Journal:  Clin Transplant       Date:  2020-06-15       Impact factor: 3.456

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.